AI Article Synopsis
- Cognitive deficits are a significant biomedical issue, and nootropic drugs, like beta-alanine and its derivatives, can help improve cognitive function.
- This study focused on a new β-alanine analogue, MB-005, to explore its nootropic effects on adult zebrafish through various behavioral tests.
- While MB-005 showed potential for enhancing short-term memory acutely, it raised concerns about impairing cognitive performance over longer periods.
Article Abstract
Background: Cognitive deficits represent an urgent biomedical problem, and are commonly reduced by nootropic drugs. Animal models, including both rodents and zebrafish, offer a valuable tool for studying cognitive phenotypes and screening novel nootropics. Beta-alanine and its derivatives have recently been proposed to exert nootropic activity.
Aims: This study aimed to characterize putative nootropic profile of a novel β-alanine analogue, 1,3-diaminopropane (MB-005), in adult zebrafish.
Methods: Nootropic profile of MB-005 was assessed in adult zebrafish in the novel tank and conditioned place aversion (CPA) tests acutely, and in cued-learning plus-maze (PMT) tests chronically.
Results/outcomes: MB-005 did not alter zebrafish anxiety-like behavior or monoamine neurochemistry acutely, improved short-term memory in the CPA test, but impaired cognitive performance in both CPA and PMT tests chronically.
Conclusions/interpretation: This study reveals high sensitivity of zebrafish cognitive phenotypes to MB-005, suggesting it as a potential novel cognitive enhancer acutely, but raises concerns over its cognitive (and, possibly, other) side-effects chronically.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/02698811221098192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!